"The
Report PharmaPoint: Colorectal Cancer - 5EU Drug Forecast and Market
Analysis to 2023 provides information on pricing, market analysis,
shares, forecast, and company profiles for key industry participants.
- MarketResearchReports.biz"
GlobalData
has released its new PharmaPoint Country Evaluation report,
PharmaPoint:
Colorectal Cancer 5EU Drug Forecast and Market
Analysis to 2023. Colorectal cancer (CRC) is the second leading cause
of mortality among cancer patients in the world and is the third most
diagnosed cancer globally, and thus represents a huge burden on
healthcare systems. This report focuses on the current treatment
landscape, unmet needs, current pipeline, and commercial
opportunities in the colorectal cancer market, with coverage of
multiple settings of the disease including neoadjuvant/adjuvant,
first-, second-, third-line KRAS wild-type and mutation-positive, and
fourth-line metastatic. In terms of targeted treatments, the
metastatic CRC treatment landscape is mature, including the branded
treatments Avastin (bevacizumab), Avastin (cetuximab), and Vectibix
(panitumumab), treatments that have extended the survival of
metastatic patients compared to chemotherapy-only regimens. However,
high unmet needs remain for the extension of survival of metastatic
patients, and particularly those with KRAS mutation-positive disease,
for whom the epidermal growth factor receptor (EGFR) inhibitors
Avastin and Vectibix are not recommended.
Growth
of the French market is expected to be driven by increasing disease
incident cases as the population ages, label extension of Stivarga as
an adjuvant treatment for resected liver metastases patients, and the
launch of expensive new therapies such as MGN-1703, a maintenance
therapy for first-line patients responding to chemotherapy with or
without biological agents. Germany has shifted towards a strict
reference pricing system and has begun implementing price cuts,
indicating that pharmaceutical companies can no longer count on the
free pricing schemes previously in place in the German market.
GlobalData believes that the government is likely to make similar
moves in the future. As in the 5EU in general, cost effectiveness is
a major priority for the Italian government and will be a major
limitation on the pricing and uptake of new drugs during the forecast
period. The Spanish government has been forced to institute severe
cost-control measures due to economic policies stemming from the 2008
financial crisis. Growth in the UK is expected to be restricted by
the NHS reimbursement watchdog, NICE. At present, no branded
treatments have been given approval from NICE in the UK.
Download
Sample copy of this Report at:
http://www.marketresearchreports.biz/sample/sample/237893
Scope
- Overview of CRC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the 5EU CRC market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for CRC
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in 5EU.
Table of Contents
1 Table of Contents 5
1.1 List of Tables 9
1.2 List of Figures 12
2 Introduction 13
2.1 Catalyst 13
2.2 Related Reports 14
2.3 Upcoming Related Reports 15
3 Disease Overview 16
3.1 Etiology and
Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 18
3.2 Clinical Staging 19
3.3 Symptoms 20
4 Disease Management 22
4.1 Diagnosis and Treatment
Overview 22
4.1.1 Screening and Diagnosis
22
4.1.2 Treatment Guidelines and
Leading Prescribed Drugs 25
4.1.3 Clinical Practice 29
4.2 France 34
4.2.1 Screening and Diagnosis
36
4.2.2 Clinical Practice 36
4.3 Germany 38
4.3.1 Screening and Diagnosis
40
4.3.2 Clinical Practice 40
4.4 Italy 42
4.4.1 Screening and Diagnosis
44
4.4.2 Clinical Practice 44
4.5 Spain 46
4.5.1 Screening and Diagnosis
48
4.5.2 Clinical Practice 48
4.6 UK 50
4.6.1 Screening and Diagnosis
52
4.6.2 Clinical Practice 52
5 Competitive Assessment 55
5.1 Overview 55
5.2 Product Profiles Major
Brands 56
5.2.1 Avastin (Bevacizumab) 56
5.2.2 Erbitux (Cetuximab) 61
5.2.3 Vectibix (Panitumumab) 65
5.2.4 Stivarga (Regorafenib) 68
5.2.5 Zaltrap (Ziv-Aflibrcept)
72
5.2.6 Lonsurf (TAS-102) 76
5.2.7 Xeloda (Capecitabine) 80
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment